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To the Editor: Pulmonary 
nontuberculous mycobacteria (NTM) 
diseases share clinical signs with 
tuberculosis (TB), causing a clinical 
dilemma with regard to therapy for 
patients with these diseases (1). In the 
past 30 years (post-AIDS era), NTM 
have increasingly been associated with 
pulmonary diseases in humans (2). 
Recent studies in urban areas of the 
People’s Republic of China have shown 
that the prevalence of NTM (isolation 
rate of NTM among all mycobacteria) 
is increasing; for example, prevalence 
in Shanghai increased from 4.26% 
in 2005 to 6.38% in 2008 (3). To 
investigate NTM prevalence in rural 
areas of China, we evaluated the NTM 
isolation rates, species distribution, 
and drug-resistance profi les through 
a population-based TB sentinel 
surveillance study in Shandong 
Province, the second largest province 
in China. The study protocol was 
approved by the Institutional Review 
Board of Shandong Provincial Chest 
Hospital (Jinan, Shandong, China). 
Clinical samples were collected 
through the ongoing sentinel TB 
surveillance project, which fi rst began 
in 7 counties in Shandong Province 
in 2004 and expanded to 13 counties 
in 2008. Of the total surveillance 
population, rural populations 
accounted for ≈80%. Each sample 
collected in this study was identifi ed 
only by a unique participant number. 
Each surveillance site sent sputum 
samples from all patients with 
suspected TB to the TB Reference 
Laboratory of Shandong Provincial 
Chest Hospital for mycobacterial 
culture, drug-susceptibility testing, 
and species identifi cation. 
From January 1, 2004, through 
December 31, 2009, Mycobacteria 
spp. were isolated from sputum 
specimens from 3,949 patients with 
suspected pulmonary TB. Of these 
patients, mean age ± SD was 48.7 ± 
20.4 years (range 1–92 years), 74.6% 
were male, and 300 were being re-
treated for TB. 
Identifi cation of Mycobacteria 
spp. was fi rst conducted by 
conventional biochemical testing—
p-nitrobenzoic acid and 2-thiophene 
carboxylic acid hydrazide testing—
following a standard protocol (4). 
Mycobacteria spp. were further 
identifi ed by 16S rRNA gene sequence 
analysis (MicroSeq ID Microbial 
Indentifi cation Software, version 2.0; 
Applied Biosystems, Foster City, 
CA, USA) to the species level as 
described (5). Drug-susceptibility 
testing was performed according to 
standard procedures recommended 
by the World Health Organization, 
and quality control was conducted by 
inter-laboratory confi rmation testing 
by reference laboratories recognized 
by the World Health Organization 
in South Korea and in Hong Kong 
Special Administrative Region, China 
(6,7). The drug panel included 4 fi rst-
line anti-TB drugs: isoniazid, rifampin, 
streptomycin, and ethambutol.
The conventional biochemical 
testing of the 3,949 Mycobacteria 
spp. strains identifi ed 68 NTM 
strains, among which the 16s rRNA 
gene sequence analysis confi rmed 64 
(1.6%) NTM strains and identifi ed 3 
M. tuberculosis complex strains and 
1 Nocardia glanders strain. Among 
the 64 NTM strains, 52 (81.2%) were 
M. intracellulare, 5 (7.8%) were M. 
kansasii, 3 (4.7%) were M. fortuitum, 
2 (3.1%) were M. chelonae, 1 (1.6%) 
was M. gordonae, and 1 (1.6%) 
was M. scrofulaceum. The fi rst-
line anti-TB drug resistance rates of 
the 64 NTM strains were 100% for 
isoniazid, 98.4% for streptomycin, 
78.1% for rifampin, and 51.6% for 
ethambutol (Table). Among the 3,949 
Mycobacteria spp. strains, 163 (4.1%) 
were resistant to at least isoniazid and 
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rifampin, of which 50 (30.7%) strains 
were identifi ed as NTM. Among 300 
TB re-treatment cases, 12 (4.0%) were 
caused by clinically signifi cant NTM 
infections. Over the 6 study years, 
NTM isolation rates among the study 
population did not show a substantial 
increasing or decreasing trend.
Our data suggest that the NTM 
isolation rate among patients with 
suspected pulmonary TB in rural 
China (1.6%) is relatively lower and 
more stable than that for urban areas 
(mean rate 5.09% in Shanghai) and that 
the Mycobacterium spp. differ from 
those in other areas of China (3,8–10). 
In China and most other developing 
countries to which TB is endemic, 
the decision to initiate pulmonary TB 
treatment is based only on fi nding a 
positive sputum smear by microscopy 
examination, not on Mycobacteria 
culture, species identifi cation, and 
drug-resistance testing results. Among 
our study population, NTM strains 
showed high drug resistance to fi rst-
line anti-TB drugs and accounted 
for 30.7% of suspected multidrug-
resistant TB (MDR-TB) cases and 
4.0% of TB re-treatment cases. 
These fi ndings suggest that 
pulmonary NTM infections pose 
substantial diffi culties with regard 
to clinical management of NTM 
and MDR-TB diseases in China. 
Laboratory species identifi cation is 
imperative before proper treatment can 
be determined for patients with MDR-
TB. Compared with conventional 
biochemical testing, 16S rRNA 
gene sequencing analysis can more 
accurately identify Mycobacteria spp. 
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Table. Species and drug-resistance profiles of 64 nontuberculous mycobacteria strains, Shandong Province, People’s Republic of 
China, 2004–2009 
Mycobacterium species 
Resistant strains, no. (%) 
Total Isoniazid Rifampin Ethambutol Streptomycin 
M. intracellulare 52 (81.2) 52 (100) 40 (76.9) 27 (51.9) 51 (98.1) 
M. kansasii 5 (7.8) 5 (100) 3 (60.0) 0 5 (100) 
M. fortuitum 3 (4.7) 3 (100) 3 (100) 2 (66.7) 3 (100) 
M. chelonae 2 (3.1) 2 (100) 2 (100) 2 (100) 2 (100) 
M. gordonae 1 (1.6) 1 (100) 1 (100) 1 (100) 1 (100) 
M. scrofulaceum 1 (1.6) 1 (100) 0 1 (100) 1 (100) 
Total 64 (100) 64 (100) 50 (78.1) 33 (51.6) 63 (98.4) 
